查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1864312

细胞冻存培养基市场按产品类型、冷冻保护剂、细胞类型、最终用户和应用划分－2025-2032年全球预测

Cell Freezing Media Market by Product Type, Cryoprotectant Agent, Cell Type, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，细胞冻存培养基市场规模将达到 4.0098 亿美元，复合年增长率为 8.97%。

主要市场统计数据
基准年 2024 2.0166亿美元
预计年份：2025年 2.1962亿美元
预测年份：2032年 4.0098亿美元
复合年增长率 (%) 8.97%

面向临床和研究相关人员，简明扼要地介绍冷冻保存介质的基本原理、配方科学、法规要求和实际操作情况。

细胞冷冻保存和冷冻培养基领域已从主要依靠经验法则发展成为一个设计严谨的领域，为治疗研发、再生医学和生物样本库等领域的许多现代进展提供了支持。对于希望维持活性细胞库、实现即用型细胞疗法以及保持诊断样本长期完整性的实验室和公司而言，清晰了解配方选择、冷冻保护剂选择以及特定应用的性能权衡至关重要。本导言整合了科学因素、生产要求和最终用户期望，为报告后续的详细分析奠定了基础。

科学进步、不断变化的临床需求、日益严格的供应链以及自动化如何共同作用，变革细胞冻存培养基的产品开发和应用？

近年来，细胞冻存液的研发、检验和应用方式发生了多项变革性变化，这些变化正在全面重塑细胞冻存液的开发方式。首先，配方技术的创新速度显着加快。从动物血清到无血清、化学成分明确的冻存液的转变，既体现了安全性方面的优先考虑，也反映了临床环境中可重复性的需求。冷冻保护剂化学技术的进步以及渗透性和非渗透性试剂的优化组合，降低了冻融应激，提高了多种细胞类型的冻存液復苏率。这些科学进步，加上生产控制的改进和高纯度原料的引入，使得细胞活力和功能的结果更加可预测。

评估美国新关税对2025年供应链和生产经济造成的营运、采购和战略影响

2025年生效的关税调整为细胞冻存培养基生态系统中的製造商、经销商和终端用户带来了新的挑战。某些原料和中间体的进口关税上调改变了采购的经济效益，尤其是对依赖国际采购的冷冻保护剂和特殊试剂供应商。即使在以往利润微薄、足以抵消成本差异的领域，关税调整也迫使许多企业重新评估其供应商组合，尽可能优先考虑国内采购，并加快替代原料的认证，以维持供应的连续性和价格的稳定。

深度細項分析揭示了产品类型、冷冻保护剂、细胞类别、最终用户和应用如何独特地影响配方要求和商业化管道。

细分市场趋势揭示了不同产品、冷冻保护剂、细胞类型、最终用户和应用领域的需求和机会。依产品类型划分，市场包括二甲基亚砜(DMSO) 培养基、甘油培养基、含血清培养基和无血清替代培养基。在这些类别中，DMSO 配方通常以 5% 和 10% 的浓度生产，以满足通讯协定的要求。甘油配方具有不同的纯度等级，以适应对纯度要求较高的製程。无血清培养基依其成分分为化学成分明确的溶液和无蛋白质溶液，以满足监管和临床规范的要求。这些产品差异至关重要，因为它们决定了操作特性、解冻后细胞活力以及与下游製程的兼容性。

区域趋势与营运要务：影响美洲、欧洲、中东和非洲以及亚太地区需求模式、监管重点和製造策略的区域趋势

区域趋势反映了各主要地区不同的驱动因素，进而影响着製造商和服务供应商的策略重点。在美洲，成熟的生物製药生态系统、高度集中的细胞疗法开发商以及完善的冷冻保存基础设施共同造就了对临床级无血清和DMSO基产品的强劲需求。同时，在欧洲、中东和非洲，监管和采购环境的分散、跨境协调工作以及不同的报销环境，使得企业必须采取适应性强的市场策略并进行多项产品註册。欧洲多个司法管辖区对安全性和可追溯性的监管重视，正在加速化学成分明确的临床级冷冻保护剂的应用。

竞争格局洞察：重点介绍临床级能力、差异化配方、供应链韧性和伙伴关係模式，这些因素共同推动了公司在市场中的领先地位。

细胞冻存培养基的竞争地位取决于技术能力、品质保证、生产规模以及满足监管应用需求的能力。领先的供应商强调采购临床级原料、严格的纯度规格和检验的工艺，以满足开展人体临床试验的申办方的需求。其他供应商则透过专注于特定领域脱颖而出，例如提供高纯度甘油製剂、无蛋白血清替代品或针对敏感细胞群（如诱导多功能细胞）优化的定製配方。将培养基开发商与医疗设备製造商、临床实验室网路和专业物流供应商联繫起来的策略联盟，进一步扩大了市场覆盖范围，并为复杂的流程提供了整合解决方案。

为供应商、製造商和最终用户提供切实可行的、优先排序的策略行动，以增强韧性、加快临床回应并促进先进冷冻保存介质的采用。

随着细胞冻存培养基市场格局的演变，产业领导者应优先考虑一系列切实可行的倡议，以获取价值并降低风险。首先，应投资开发和验证无血清、化学成分明确的配方，以满足临床开发人员日益增长的需求，并降低动物性成分带来的变异性。同时，应重点关注临床级冷冻保护剂的合格，并完善供应链文件，以满足监管和临床检验要求。其次，应实现供应商多元化，并扩大区域製造地，以降低关税带来的成本压力和物流中断风险。关键原料的近岸外包或双重采购可以显着提高企业的抗风险能力。

我们采用透明的混合方法调查方法，结合对主要相关人员的访谈、技术文献的综合分析以及对监管和产品文件的检验，以确保得出可靠的研究结果。

本分析采用混合研究途径，结合了访谈、产品和文献综述以及对公开监管技术文件的系统性检验。主要输入包括对製剂科学家、品管人员、采购经理和临床用户的结构化访谈，以收集有关性能优先事项、供应链限制因素和监管准备的第一手资讯。这些定性研究结果与技术出版物、白皮书、监管指南和产品文件的审查结果进行三角验证，以确保其与既定的最佳实践和最新科学进展保持一致。

整合科学、监管和供应链趋势，以明确利害关係人的策略重点，帮助他们利用冷冻保存和细胞冻存培养基的进步。

摘要，细胞冻存培养基领域目前处于配方科学、临床需求和供应链管理三者交会点。无血清和化学成分明确的产品的进步，以及对临床级成分和可重复工作流程的重视，提高了终端用户对培养基供应商的期望。同时，政策趋势和贸易调整凸显了来源多元化和区域生产策略对于确保关键成分持续供应的重要性。这些因素正在共同重塑研发企业的投资重点，并推动那些兼具卓越技术、法规遵循和物流能力的公司获得溢价。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 在细胞治疗生产中更广泛地采用无异种成分和无血清的冻存培养基，可提高安全性和一致性。
  • 开发低二甲基亚砜保护剂可降低敏感细胞株解冻后的细胞毒性。
  • 整合自动化冷冻系统以提高生物银行操作的可重复性和通量。
  • 用于干细胞构建体长期冷冻保存的新兴可生物降解水凝胶封装技术
  • 常温稳定型冷冻保护剂的广泛应用简化了全球细胞分销的物流。
  • 引入符合规范的一次性冷冻保存袋和冷冻保存管瓶，以最大限度地降低临床工作流程中的污染风险。
  • 适用于冻融后iPS细胞扩增的高活性冷冻保护添加剂的研发进展
  • 协调国际细胞冻存培养基监管指南将简化跨境细胞治疗核准。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的细胞冻存培养基市场

  • 基于DMSO的冷冻保存介质
    • 5% DMSO
    • 10% DMSO
  • 甘油培养基
    • 高纯度甘油
    • 标准甘油
  • 含血清培养基
  • 无血清培养基
    • 化学合成
    • 不含蛋白质

9. 依冷冻保护剂分類的细胞冻存培养基市场

  • 二甲基亚砜
    • 临床等级
    • 标准级
  • 乙二醇
  • 甘油
  • 丙二醇

第十章 依细胞类型分類的细胞冻存培养基市场

  • 免疫细胞
  • 微生物细胞
  • 体细胞
  • 干细胞
    • 成体干细胞
    • 胚胎干细胞
    • 诱导性多功能干细胞

第十一章 细胞冻存培养基市场（依最终用户划分）

  • 生物製药公司
  • 细胞库
  • 临床检查室
  • 研究所

第十二章 细胞冻存液市场（依应用划分）

  • 基础研究
  • 细胞疗法
    • 同种异体移植疗法
    • 自体疗法
  • 药物发现
  • 生育力保存

第十三章 各地区细胞冻存培养基市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 细胞冻存液市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国细胞冻存培养基市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Lonza Group AG
    • Corning Incorporated
    • Avantor, Inc.
    • STEMCELL Technologies Inc.
    • BioLife Solutions, Inc.
    • Miltenyi BIoTec GmbH
    • PromoCell GmbH
Product Code: MRR-3F223D524794

The Cell Freezing Media Market is projected to grow by USD 400.98 million at a CAGR of 8.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 201.66 million
Estimated Year [2025] USD 219.62 million
Forecast Year [2032] USD 400.98 million
CAGR (%) 8.97%

A concise orientation to cell freezing media fundamentals, bridging formulation science, regulatory expectations, and operational realities for clinical and research stakeholders

The field of cryopreservation and cell freezing media has matured from a largely empirical practice into a rigorously engineered discipline that underpins many contemporary advances in therapeutic development, regenerative medicine and biological repositories. A clear understanding of formulation choices, cryoprotectant selection, and application-driven performance trade-offs is now a prerequisite for laboratories and companies aiming to sustain viable cell stocks, enable off-the-shelf cell therapies, or maintain diagnostic sample integrity over time. This introduction synthesizes scientific drivers, manufacturing imperatives, and end-user expectations to frame the subsequent, deeper analysis contained in the report.

Transitioning from basic laboratory recipes to validated, scalable products requires close alignment between formulation science and quality systems. Developers must reconcile cryoprotective efficacy, cytotoxicity, regulatory compatibility, and supply continuity, while end users increasingly demand serum-free, chemically defined, and clinically compliant media. As adoption expands across biopharma, fertility services, and research institutes, the intersection of product innovation and operational reliability determines which offerings achieve broad clinical and commercial acceptance. The following sections explore the structural changes reshaping the market and the strategic implications for stakeholders across the value chain.

How scientific advances, clinical demand evolution, supply chain rigor, and automation are converging to transform product development and adoption of cell freezing media

Recent years have seen several transformative shifts that collectively redefine how cell freezing media are developed, validated, and deployed. First, formulation innovation has accelerated: the movement away from animal serum toward serum-free and chemically defined options reflects both safety priorities and the need for reproducibility in clinical settings. Advances in cryoprotectant chemistry and optimized combinations of permeating and non-permeating agents have reduced freeze-thaw stress and improved post-thaw recovery across diverse cell types. These scientific gains are coupled with improved manufacturing controls and higher-purity raw materials, enabling more predictable outcomes in cell viability and function.

Second, the proliferation of cell and gene therapies has reshaped demand profiles. End users require media formulated specifically for sensitive cell populations such as stem cells and immune cells, with growing emphasis on clinical-grade components and validated supply chains. Third, regulatory frameworks and quality expectations have tightened; manufacturers are investing in robust characterization, stability data, and traceability to satisfy clinical trial sponsors and regulators. Finally, digitization and automation in cryopreservation workflows-ranging from controlled-rate freezers to standardized thawing devices-are reducing operator variability and enabling scalable, reproducible processes for both research and clinical applications. Together these shifts create a landscape where product differentiation, supply reliability, and regulatory preparedness determine competitive advantage.

Assessment of the operational, procurement, and strategic consequences stemming from new United States tariff measures affecting supply chains and production economics in 2025

Tariff policy changes enacted in the United States in 2025 introduced a new layer of complexity for manufacturers, distributors, and end users engaged in the cell freezing media ecosystem. Increased import duties on select raw materials and intermediates have altered procurement economics, particularly for suppliers who rely on internationally sourced cryoprotectants or specialty reagents. Where previously cost differentials could be absorbed at thin margins, the tariff adjustments have prompted many organizations to reevaluate supplier portfolios, prioritize domestic sourcing where feasible, and accelerate qualification of alternative inputs to maintain continuity and price stability.

Beyond procurement, the cumulative tariff impact has influenced strategic decisions around manufacturing location and inventory policy. Some companies have explored nearshoring or regional production to mitigate exposure to cross-border duties and the logistics volatility that accompanies them. Others have adopted more conservative inventory strategies-building safety stock of key components to dampen short-term cost shocks-while recognizing the operational and capital implications of larger holdings. For research institutes and clinical labs, increased input costs have translated into heightened scrutiny of per-sample cost and an urgency to validate lower-cost, serum-free formulations that maintain performance. Ultimately, policy-driven cost pressures have elevated resilience and supply diversification to the top of the strategic agenda for stakeholders across the value chain.

Deep segmentation analysis revealing how product types, cryoprotectants, cell categories, end users, and applications uniquely shape formulation requirements and commercialization paths

Segment-level dynamics illuminate differentiated needs and opportunities across products, cryoprotectants, cell types, end users, and applications. In terms of product type, the market composition spans dimethyl sulfoxide (DMSO) based media, glycerol based media, serum-containing media, and serum-free alternatives; within those categories, DMSO formulations are commonly manufactured at five percent and ten percent concentrations to match protocol requirements, glycerol variants differ by purity grade to support sensitive processes, and serum-free options are split between chemically defined and protein-free solutions to meet regulatory and clinical specifications. These product distinctions matter because they determine handling characteristics, post-thaw viability, and compatibility with downstream workflows.

When viewed through the lens of cryoprotectant agents, the choice among dimethyl sulfoxide, ethylene glycol, glycerol, and propylene glycol drives formulation strategy, with DMSO further segmented into clinical-grade and standard-grade tiers that align with therapeutic versus research use cases. Cell type segmentation highlights that immune cells, microbial cells, somatic cells, and stem cells present unique preservation challenges; stem cell subcategories such as adult, embryonic, and induced pluripotent stem cells often require tailored cryoprotectant regimes and stricter manufacturing controls. End-user segmentation distinguishes between biopharmaceutical companies, cell banks, clinical laboratories, and research institutes, each of which imposes distinct requirements for traceability, batch consistency, and regulatory documentation. Finally, application-focused segmentation-covering basic research, cell therapy, drug discovery, and fertility preservation-reveals divergent priorities around sterility, long-term viability, and scalability, with cell therapy further divided into allogeneic and autologous workflows that affect formulation selection and logistical demands.

Regional dynamics and operational imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine demand patterns, regulatory priorities, and manufacturing strategies

Regional dynamics reflect divergent drivers across major geographies and influence strategic priorities for manufacturers and service providers. The Americas exhibit strong demand driven by a mature biopharma ecosystem, a high concentration of cell therapy developers, and well-established cryobanking infrastructure, which together create robust demand for clinical-grade, serum-free and DMSO-based products. In contrast, Europe, Middle East & Africa presents a fragmented regulatory and procurement landscape where cross-border harmonization efforts and differing reimbursement environments necessitate adaptable market strategies and multiple product registrations. Regulatory emphasis on safety and traceability in several European jurisdictions has accelerated adoption of chemically defined and clinical-grade cryoprotectants.

Asia-Pacific shows a heterogeneous mix of advanced centers of excellence and rapidly scaling research capacity. Investment in cell therapy development and fertility services is significant in select Asia-Pacific markets, stimulating demand for both standardized commercial media and locally adapted formulations. Regional manufacturing capacity expansion is visible as suppliers seek to localize production and reduce lead times for key ingredients. Across all regions, supply chain resilience, regulatory alignment, and the ability to service clinical trial needs remain decisive factors shaping where companies invest and how they structure commercial partnerships.

Competitive landscape insights emphasizing clinical-grade capability, formulation differentiation, supply chain robustness, and partnership models that drive market leadership

Competitive positioning in cell freezing media is determined by technical capability, quality assurance, manufacturing scale, and the ability to support regulated applications. Leading suppliers emphasize clinical-grade sourcing, rigorous purity specifications, and validated processes to satisfy sponsors conducting human trials. Others differentiate through niche expertise, offering high-purity glycerol variants, protein-free serum alternatives, or bespoke formulations optimized for sensitive cell populations such as induced pluripotent stem cells. Strategic partnerships-linking media developers with device manufacturers, clinical trial networks, or specialized logistics providers-further extend reach and facilitate integrated solutions for complex workflows.

Manufacturers with established cold-chain logistics and global distribution networks can address multinational clinical programs more effectively, while smaller, highly specialized producers often compete on formulation performance and customer support. Investment in analytical characterization, stability testing, and batch release criteria is a clear marker of companies prepared for clinical and commercial adoption. Additionally, entrants offering companion services-such as cryopreservation protocol consulting, training, and qualification kits-are increasingly attractive to end users seeking to de-risk implementation. Overall, the competitive landscape rewards a combination of regulatory readiness, product reliability, and close technical collaboration with end-user organizations.

Practical and prioritized strategic actions for suppliers, manufacturers, and end users to strengthen resilience, accelerate clinical readiness, and improve adoption of advanced cryopreservation media

Industry leaders should prioritize a set of actionable initiatives to capture value and mitigate risk as the cell freezing media environment evolves. First, invest in developing and validating serum-free and chemically defined formulations to meet growing demand from clinical developers and to reduce variability associated with animal-derived components. Parallel efforts should focus on qualifying clinical-grade cryoprotectants and documenting supply chains to meet regulatory expectations and clinical trial requirements. Second, strengthen supplier diversification and regional manufacturing footprint to reduce exposure to tariff-driven cost pressures and logistics disruptions; nearshoring or dual-sourcing critical raw materials can materially increase resilience.

Third, enhance technical support and service offerings by providing validated protocols, training, and thawing guidance that reduce operator variability and improve adoption rates. Fourth, pursue strategic alliances with device makers, contract manufacturers, and clinical networks to offer integrated end-to-end solutions that simplify cell therapy workflows. Fifth, allocate R&D resources to address the unique preservation needs of high-value cell types, such as stem cells and immune cell therapies, ensuring formulations are optimized for functional recovery post-thaw. Finally, maintain a disciplined regulatory and quality roadmap that anticipates documentation needs for clinical use, enabling faster approvals and reduced time to market for customers deploying cell-based interventions.

Transparent mixed-methods research approach combining primary stakeholder interviews, technical literature synthesis, and validation against regulatory and product documentation to ensure robust findings

This analysis is grounded in a mixed-methods research approach combining primary interviews, product and literature synthesis, and systematic validation against publicly available regulatory and technical documents. Primary inputs included structured interviews with formulation scientists, quality leaders, procurement managers, and clinical users to capture first-hand perspectives on performance priorities, supply chain constraints, and regulatory preparedness. These qualitative insights were triangulated with a review of technical publications, white papers, regulatory guidance, and product documentation to ensure alignment with established best practices and recent scientific advances.

Data integrity was reinforced through cross-validation of supplier claims, assessment of material safety and purity standards, and an examination of clinical study protocols where cell freezing media were specified. The analysis also incorporated scenario-based evaluation of supply chain disruptions and tariff impacts to assess strategic options. Limitations include variability in proprietary formulation details and the confidential nature of some commercial agreements, which can constrain visibility into specific pricing arrangements. Where appropriate, assumptions and evidence sources are transparently documented within the full report to support reproducibility and further analysis.

Synthesis of scientific, regulatory, and supply chain developments that delineate strategic priorities for stakeholders aiming to harness advancements in cryopreservation and cell freezing media

In sum, the cell freezing media domain now sits at the intersection of formulation science, clinical demand, and supply chain discipline. Progress in serum-free and chemically defined products, coupled with an emphasis on clinical-grade inputs and reproducible workflows, has raised the bar for what end users expect from media suppliers. Concurrently, policy movements and trade adjustments have underscored the importance of supply diversification and regional manufacturing strategies for ensuring continuity of critical inputs. Taken together, these forces are reshaping investment priorities for developers and driving a premium for companies that can combine technical excellence with regulatory and logistical competence.

For stakeholders across biopharma, clinical laboratories, and research institutions, the implications are clear: prioritize validated, application-specific media; invest in quality systems and supplier risk management; and seek partners who can provide both technical support and secure distribution. As cell-based therapies continue to mature and the expectations around product consistency and traceability increase, the organizations that align formulation innovation with operational resilience will be best positioned to serve the needs of an expanding and demanding marketplace.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of xeno-free and serum-free freezing media in cell therapy manufacturing to enhance safety and consistency
  • 5.2. Development of low dimethyl sulfoxide based cryoprotectants to reduce post-thaw cytotoxicity in sensitive cell lines
  • 5.3. Integration of automated controlled rate freezing systems to improve reproducibility and throughput in biobanking operations
  • 5.4. Emergence of biodegradable hydrogel encapsulation techniques for long term cryopreservation of stem cell constructs
  • 5.5. Rise of ambient temperature stable cryopreservation formulations enabling simplified logistics for global cell distribution
  • 5.6. Implementation of regulatory compliant single use cryopreservation bags and vials to minimize contamination risks in clinical workflows
  • 5.7. Advancements in high viability cryoprotective additives tailored for induced pluripotent stem cell expansion post-thaw
  • 5.8. Harmonization of international regulatory guidelines for cell freezing media to streamline cross border cell therapy approvals

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Freezing Media Market, by Product Type

  • 8.1. DMSO Based Media
    • 8.1.1. Five Percent DMSO
    • 8.1.2. Ten Percent DMSO
  • 8.2. Glycerol Based Media
    • 8.2.1. High Purity Glycerol
    • 8.2.2. Standard Glycerol
  • 8.3. Serum Containing Media
  • 8.4. Serum Free Media
    • 8.4.1. Chemically Defined
    • 8.4.2. Protein Free

9. Cell Freezing Media Market, by Cryoprotectant Agent

  • 9.1. Dimethyl Sulfoxide
    • 9.1.1. Clinical Grade
    • 9.1.2. Standard Grade
  • 9.2. Ethylene Glycol
  • 9.3. Glycerol
  • 9.4. Propylene Glycol

10. Cell Freezing Media Market, by Cell Type

  • 10.1. Immune Cells
  • 10.2. Microbial Cells
  • 10.3. Somatic Cells
  • 10.4. Stem Cells
    • 10.4.1. Adult Stem Cells
    • 10.4.2. Embryonic Stem Cells
    • 10.4.3. Induced Pluripotent Stem Cells

11. Cell Freezing Media Market, by End User

  • 11.1. Biopharmaceutical Companies
  • 11.2. Cell Banks
  • 11.3. Clinical Laboratories
  • 11.4. Research Institutes

12. Cell Freezing Media Market, by Application

  • 12.1. Basic Research
  • 12.2. Cell Therapy
    • 12.2.1. Allogeneic Therapy
    • 12.2.2. Autologous Therapy
  • 12.3. Drug Discovery
  • 12.4. Fertility Preservation

13. Cell Freezing Media Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell Freezing Media Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell Freezing Media Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Merck KGaA
    • 16.3.3. Danaher Corporation
    • 16.3.4. Lonza Group AG
    • 16.3.5. Corning Incorporated
    • 16.3.6. Avantor, Inc.
    • 16.3.7. STEMCELL Technologies Inc.
    • 16.3.8. BioLife Solutions, Inc.
    • 16.3.9. Miltenyi Biotec GmbH
    • 16.3.10. PromoCell GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL FREEZING MEDIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CRYOPROTECTANT AGENT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CRYOPROTECTANT AGENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CELL FREEZING MEDIA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CELL FREEZING MEDIA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL FREEZING MEDIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL FREEZING MEDIA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL FREEZING MEDIA MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY FIVE PERCENT DMSO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY FIVE PERCENT DMSO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY FIVE PERCENT DMSO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY FIVE PERCENT DMSO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY FIVE PERCENT DMSO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY FIVE PERCENT DMSO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY TEN PERCENT DMSO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY TEN PERCENT DMSO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY TEN PERCENT DMSO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY TEN PERCENT DMSO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY TEN PERCENT DMSO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY TEN PERCENT DMSO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY HIGH PURITY GLYCEROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY HIGH PURITY GLYCEROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY HIGH PURITY GLYCEROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY HIGH PURITY GLYCEROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY HIGH PURITY GLYCEROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY HIGH PURITY GLYCEROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STANDARD GLYCEROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STANDARD GLYCEROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STANDARD GLYCEROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STANDARD GLYCEROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STANDARD GLYCEROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STANDARD GLYCEROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM CONTAINING MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM CONTAINING MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM CONTAINING MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM CONTAINING MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM CONTAINING MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM CONTAINING MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CHEMICALLY DEFINED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CHEMICALLY DEFINED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CHEMICALLY DEFINED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CHEMICALLY DEFINED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CHEMICALLY DEFINED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CHEMICALLY DEFINED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PROTEIN FREE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PROTEIN FREE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PROTEIN FREE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PROTEIN FREE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PROTEIN FREE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PROTEIN FREE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CRYOPROTECTANT AGENT, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CRYOPROTECTANT AGENT, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CLINICAL GRADE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CLINICAL GRADE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CLINICAL GRADE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CLINICAL GRADE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CLINICAL GRADE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CLINICAL GRADE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STANDARD GRADE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STANDARD GRADE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STANDARD GRADE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STANDARD GRADE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STANDARD GRADE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STANDARD GRADE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ETHYLENE GLYCOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ETHYLENE GLYCOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ETHYLENE GLYCOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ETHYLENE GLYCOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ETHYLENE GLYCOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ETHYLENE GLYCOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PROPYLENE GLYCOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PROPYLENE GLYCOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PROPYLENE GLYCOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PROPYLENE GLYCOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PROPYLENE GLYCOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY PROPYLENE GLYCOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY IMMUNE CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY IMMUNE CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY IMMUNE CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY IMMUNE CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY IMMUNE CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY IMMUNE CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY MICROBIAL CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY MICROBIAL CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY MICROBIAL CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY MICROBIAL CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY MICROBIAL CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY MICROBIAL CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SOMATIC CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SOMATIC CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SOMATIC CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SOMATIC CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SOMATIC CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY SOMATIC CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ADULT STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ADULT STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ADULT STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ADULT STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ALLOGENEIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ALLOGENEIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ALLOGENEIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ALLOGENEIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ALLOGENEIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY ALLOGENEIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY AUTOLOGOUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY AUTOLOGOUS THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY AUTOLOGOUS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY AUTOLOGOUS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY AUTOLOGOUS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY AUTOLOGOUS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY FERTILITY PRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY FERTILITY PRESERVATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY FERTILITY PRESERVATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY FERTILITY PRESERVATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY FERTILITY PRESERVATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY FERTILITY PRESERVATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CELL FREEZING MEDIA MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY CRYOPROTECTANT AGENT, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY CRYOPROTECTANT AGENT, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY CRYOPROTECTANT AGENT, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY CRYOPROTECTANT AGENT, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY CRYOPROTECTANT AGENT, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY CRYOPROTECTANT AGENT, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA CELL FREEZING MEDIA MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY DMSO BASED MEDIA, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY GLYCEROL BASED MEDIA, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY SERUM FREE MEDIA, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY CRYOPROTECTANT AGENT, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY CRYOPROTECTANT AGENT, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY DIMETHYL SULFOXIDE, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA CELL FREEZING MEDIA MARKET SIZE, BY